Alpha 1 Antitrypsin Deficiency Clinical Trials

A listing of Alpha 1 Antitrypsin Deficiency medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Featured trial
Alpha-1 Study: A research study for individuals with Alpha-1 Antitrypsin Deficiency

The Alpha-1 Study is a clinical research study currently enrolling individuals 18 to 78 (inclusive) with Alpha-1 Antitrypsin Deficiency.   The purpose of this study is to evaluate

deficiency
alpha 1-antitrypsin
alpha1-proteinase inhibitor (human)
  • 232 views
  • 23 Nov, 2020
  • 7 locations
Featured trial
Role of Genetic Factors in the Pathogenesis of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes …

bronchoscopy
diabetes
pulmonary disease
pulmonary fibrosis
  • 352 views
  • 23 Nov, 2020
  • 1 location
Study of OsrhAAT or Placebo in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Ascending Doses of OsrhAAT in Healthy Volunteers

platelet count
body mass index
absolute neutrophil count
Accepts healthy volunteers
  • 0 views
  • 06 May, 2022
  • 1 location
A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease (ESTRELLA)

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ A1ATD-associated liver

alpha1-proteinase inhibitor (human)
  • 2 views
  • 02 Jul, 2022
  • 12 locations
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses …

  • 755 views
  • 13 Mar, 2022
  • 44 locations
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency (ATALANTa)

oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as PiZZ, PiSZ, Pi*null, or another rare phenotype/genotype known to be associated with either low (serum AAT

deficiency
COPD
alpha1-proteinase inhibitor (human)
emphysema
chronic obstructive pulmonary disease
  • 498 views
  • 02 Feb, 2022
  • 9 locations
Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD (InnovAATe)

of adult patients with congenital alpha-1 antitrypsin (AAT) deficiency who have moderate airflow limitation (forced expiratory volume in 1 second 50% [FEV1] 80% of predicted) and FEV1/slow vital

lung disease
deficiency
neutrophil elastase
protease inhibitor
washed out
  • 32 views
  • 21 Feb, 2022
  • 1 location
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (rhAAT-Fc)

This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.

deficiency
iv immunoglobulins
alpha1-proteinase inhibitor (human)
drug trials
bronchoscopy
  • 250 views
  • 23 Mar, 2022
  • 10 locations
Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

This is a single centre exploratory study that aims to apply hyperpolarized xenon-129 (129Xe) magnetic resonance imaging (MRI) methods and measurements in individual patients with and without lung disease to better understand lung structure and function and evaluate response to therapy delivered as a part of clinical care.

bronchiectasis
fibrosis
sarcoidosis
respiratory infection
bronchopulmonary dysplasia
  • 547 views
  • 27 Feb, 2022
  • 1 location
  • 0 views
  • 21 Mar, 2022
  • 4 locations